Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

Jun 05, 2017 09:09AM

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

in response to

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

posted on Jun 05, 2017 11:22AM

I wonder if this patent issuance was a catalyst for a pending upcoming deal?

1 Recommendations

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

Jun 05, 2017 12:01PM

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention